Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
25,820 people get PFE articles and Market Currents by email alert.
Get email alerts on PFE »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
Pfizer's CEO Discusses Q3 2012 Results - Earnings Call TranscriptThu, Nov 1, 2012 • 1 Comment
-
Pfizer's CEO Discusses Q2 2012 Results - Earnings Call TranscriptTue, Jul 31, 2012 • 2 Comments
-
Pfizer's CEO Discusses Q1 2012 Results - Earnings Call TranscriptTue, May 1, 2012
-
Pfizer's CEO Hosts 2012 Annual Meeting (Transcript)Thu, Apr 26, 2012 • 2 Comments
-
Pfizer's CEO Discusses Q4 2011 Results - Earnings Call TranscriptTue, Jan 31, 2012 • 1 Comment
-
Pfizer's CEO Discusses Q3 2011 Results - Earnings Call TranscriptTue, Nov 1, 2011
-
Pfizer's CEO Discusses Q2 2011 Results - Earnings Call TranscriptTue, Aug 2, 2011
-
Pfizer's CEO Discusses Q1 2011 Results - Earnings Call TranscriptTue, May 3, 2011 • 1 Comment
-
Pfizer's CEO Discusses Q4 2010 Results - Earnings Call TranscriptTue, Feb 1, 2011 • 1 Comment
-
Pfizer CEO Discusses Q3 2010 Results - Earnings Call TranscriptTue, Nov 2, 2010
-
Pfizer Q2 2010 Earnings Call TranscriptTue, Aug 3, 2010
-
Pfizer Q1 2010 Earnings Call TranscriptTue, May 4, 2010
-
Pfizer Inc. Q4 2009 Earnings Call TranscriptWed, Feb 3, 2010
-
Pfizer, Inc. Q3 2009 Earnings Call TranscriptTue, Oct 20, 2009
-
Pfizer Inc. Q2 2009 Earnings Call TranscriptWed, Jul 22, 2009
-
Pfizer Q1 2009 Earnings Call TranscriptTue, Apr 28, 2009
-
Pfizer Q4 2008 Earnings and Conference Call TranscriptWed, Jan 28, 2009
-
at Fox Business (Thu, 11:00PM)
-
at CNBC.com (Wed, 5:25PM)
-
at MarketWatch.com (Wed, 4:10PM)
-
at Fox Business (Wed, 9:41AM)
-
at CNBC.com (Jun 12, 2013)
-
Business Wire (Jun 12, 2013)
-
at Fox Business (Jun 12, 2013)
-
at Fox Business (Jun 12, 2013)
-
Business Wire (Jun 6, 2013)
-
at MarketWatch.com (Jun 5, 2013)
-
at CNBC.com (Jun 3, 2013)
-
Business Wire (May 28, 2013)
-
at Fox Business (May 23, 2013)
-
at CNBC.com (May 22, 2013)
-
at Fox Business (May 22, 2013)
-
Business Wire (May 22, 2013)
-
at Fox Business (May 22, 2013)
-
at CNBC.com (May 21, 2013)
PFE vs. ETF Alternatives
Company Description
Pfizer Inc. (which may be referred to as Pfizer, the Company, we, us or our) is a research-based, global biopharmaceutical company. We apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, June 17, 4:27 PM Zoetis (ZTS +0.5%) says it's joining the S&P 500 index, after Pfizer (PFE) splits off its remaining 80% stake in the animal-medicine company. It will replace First Horizon (FHN), which is replacing QLogic (QLGC) in the S&P MidCap 400 index. 1 Comment [Healthcare]
- Thursday, June 13, 8:15 AM Tobacco companies (MO, PM, LO, RAI, BTI, ITYBY.PK) think they have the answer to where to find revenue growth with the advent of electronic cigarettes across the world, even as regulators struggle with the concept of if "safer" products are tolerable enough to allow the devices to work as a gateway to reducing nicotine addiction. If the future of e-cigarettes is as bright as tobacco players make it out to be, Pfizer (PFE) and GlaxoSmithKline (GSK) could see demand for their own nicotine addiction products turn lower. Comment! [Consumer]
- Wednesday, June 12, 8:39 AM More on Protonix settlement: Teva (TEVA -1.3%) will pay $1.6B of the $2.15B, half in 2013 and the rest by October 2014, while Sun will pay its $550M share this year. The settlement follows a legal battle of almost 10 years in which a jury found that Teva and Sun violated the patent by launching generic versions of Protonix prior to the expiry of its patent in 2011. The deal also comes after the start of a trial to determine damages. Pfizer (PFE) +0.8%. (PR) 4 Comments [Healthcare, Top Stories]
- Wednesday, June 12, 7:56 AM Pfizer (PFE) and Takeda (TKPHF.PK) obtain a $2.15B settlement from Teva (TEVA) and India's Sun for breaching a patent of Pfizer's and Nycomed's (now part of Takeda) blockbuster acid reflux medicine Protonix. Pfizer will receive 64% of the money and Takeda the rest. (PR) Comment! [Breaking News, Healthcare, Top Stories]
- Friday, June 7, 1:24 PM Jefferies is out with some price target revisions and color after conducting a "global pharma review." Rundown: Top U.S. pick Abbott Laboratories (ABT +1.9%) reiterated at Buy, PT lowered to $44 from $46; top global pick Novartis (NVS +0.3%) has "positive growth inflection potential" in FY14; AbbVie (ABBV +0.6%), Roche (RHHBY.OB +2.5%), and Sanofi (SNY +0.5%) offer "attractive entry points" but ABBV's PT is lowered to $51 from $54; Johnson & Johnson's (JNJ +0.2%) PT lowered to $91 from $97; Merck (MRK -0.3%) has its price target raised to $56 from $54 and Pfizer (PFE +1.3%) has its target lowered slightly to $32. (Previous: Jefferies SOTP analysis) 3 Comments [Healthcare, On the Move]
- Thursday, June 6, 9:37 AM Western drugs for baldness are gaining ground in China from traditional herbal remedies and even more esoteric treatments such as snake gall bladders. The market is small but has surged 90% to 100.7M yuan ($16.4M) in five years, and it looks like it could grow much further: in one survey, 47% of respondents said they had sought help for their hair loss. Companies that could benefit include Merck (MRK), J&J (JNJ), Pfizer (PFE) and L'Oreal (LRLCF.PK). 2 Comments [Healthcare]
- Wednesday, June 5, 2:47 PM A study in the European Heart Journal suggests Alzheimer's drugs such as Pfizer (PFE -0.6%) and Eisai's (ESALF.PK) Aricept, Novartis' (NVS -1.3%) Exelon, and Johnson & Johnson's (JNJ -0.4%) Razadyne may reduce the risk of heart attacks and death. 2 Comments [Healthcare]
- Saturday, June 1, 11:26 PM Pfizer's (PFE) Xalkori (crizotinib) — approved in August of 2011 for the treatment of non-small cell lung cancer patients who are ALK-positive — shows promise in extending progression-free survival when compared with the chemotherapy drugs pemetrexed and docetaxel, data from a clinical trial shows. The drug had sales of $53M in Q1. (WSJ) Comment! [Healthcare]
- Wednesday, May 29, 2:18 PM Pfizer (PFE -2%) says that UPM Pharmaceuticals, a Baltimore-based drug development and contract manufacturer, has acquired the 500K square-foot commercial manufacturing facility that PFE currently operates in Bristol, Tenn. The new facility gives UPM the capability to annually produce 3.5B tablets and 680M capsules. As part of the purchase, UPM will continue to manufacture PFE's current portfolio of products within the facility for two years. Comment! [Healthcare, On the Move]
- Friday, May 24, 7:27 AM Pfizer's (PFE) price target is hiked a buck to $29 at MKM Partners as the earlier-than-expected Zoetis (ZTS) spinoff has the team cutting their 2013 EPS forecast to $2.17 from $2.23, but raising estimates from 2014-17. The company remains a Hold however, as it's trading just above what MKM considers fair-value. Comment! [Healthcare]
- Wednesday, May 22, 11:07 AM AIG remains at the top Goldman's list of hedge fund hotels (the 50 stocks appearing most frequently among hedge fund top 10 holdings). Google (GOOG) retains its #2 position. Apple (APPL) - in the top spot for 3 years until February - remains at #3. Goldman notes the basket has outperformed the S&P a bit this year and the top 20 has done better by more than 1000 basis points. We smell an ETF offering. The rest of the top 20: C, GM, PCLN, VMED, NWSA, MSFT, HTZ, JPM, APC, PFE, QCOM, CHTR, HES, CBS, EBAY, DAL, EQIX. 4 Comments
- Wednesday, May 22, 8:18 AM Pfizer (PFE) plans to spin off its remaining stake in Zoetis (ZTS) through a tax-free exchange offer in which Pfizer owners can exchange their Pfizer shares for stock in Zoetis owned by Pfizer (got that?). Pfizer has received a waiver of the 180-day lock-up from the book runners of the Zoetis IPO. PFE +2.1%, ZTS -1.2% premarket. (PR) 11 Comments [Healthcare, Breaking News, On the Move]
- Monday, May 20, 5:23 PM Pfizer (PFE) says it's discontinuing Phase 3 studies on its investigational compound inotuzumab ozogamicin in combination with rituximab, a treatment for patients with non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy, after the study failed to meet its primary objective of improving overall survival. No new or unexpected safety issues were identified, and PFE says it's continuing to review the the drug for potential subset applications. Shares -0.3% AH. Comment! [Healthcare]
- Friday, May 10, 8:12 AM Pain Therapeutics (PTIE) craters 45.5% in premarket trading after Pfizer (PFE) says it is "considering its options" on Remoxy and may not respond to the FDA's complete response letter anytime in the next two years. PTIE sub-licensed Remoxy's commercialization rights to PFE subsidiary King Pharma (I, II). Comment! [Healthcare, On the Move]
- Friday, May 10, 7:46 AM Pfizer (PFE) updates Durect (DRRX) on Remoxy, saying that it's "considering its options", and that if it elects to continue development of Remoxy, "we would not expect to submit a response to the "complete response" letter before mid-2015." (PR) This is less positive than expected by SA author Jason Napodano; shares are -12.6% premarket. 1 Comment [Healthcare, On the Move, Breaking News]
- Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Joseph P. Porter
$PFE was giving me the willies for a while. Finally looks to be back on track. Will it see $30 again soon? - View all 0 replies
-
- View all 2 replies
-
-
-
- View all 0 replies
-
- View all 0 replies
-
Dividend Sheet
$JPM $PFE and $GE are the most recommended Dogs of the Dow Jones - http://stks.co/pEMN - 10 shares with 3.45% Average Yield - View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
DAG1996: went ahead and added at $28.10 ... probably too early but still keeps my average below $24 so that's okay
LATEST REPLIES
-
- View all 2 replies
-
-
-
- View all 1 replies
-
DAG1996: went ahead and added at $28.10 ... probably too early but still keeps my average below $24 so that's okay
-
- View all 7 replies
-
Chines33: Yes typically. It all depends on situation. Price, company, news, overall market. Lot of variables.
-
wheelz23: i was swing trading, but have been day trading...it seems like swing trading is less work, more money for the stocks i was trading...thanks
-
- View all 4 replies
-
-
-
Joseph P. Porter
$PFE making another run to go over $30.00. Maybe they'll manage to stay up there this time - or have they hit the ceiling? - View all 3 replies
-
Joseph P. Porter: If they were to get some bad news it might help bring the price down a little bit, but I think last week was their down week.
-
-
- View all 1 replies
-
-
- View all 5 replies
-
neobliviscar: Ja mata. Let me frame it then. The stock is only up +10% this week. It was up +11%, except for that Charlie Sheen Violent Torpedo of Truth. -
-
Joseph P. Porter
$PFE pfaithfully pfollows its tradition of offering its divs - $0.24 to be paid in June. Pfar out. - View all 3 replies
-
Joseph P. Porter: Absolutely pfabulous, in my book. Pfizer is to dividends what prunes are to BM's - regularity exemplified. $PFE is pfar and away the best
-
Joseph P. Porter: company I have shares in. So pfar, more than 30% return, not counting divs. Pfortunately, I bought in over a year ago.
-
The Hammer
$PFE breaking out multi-year highs. Lots of investors jumped ship early on this one. It is getting close to oversold. how far does this run? - View all 6 replies
-
The Hammer: Broke above $30 nice. however the pure pharma business model is riskier than the nvs or jnj model more preferred. Hope it runs fast
-
The Hammer: will lighten up into a nice spike from here. reinvested every div over something like 7 years or so.
-
- View all 4 replies
-
Chines33: Only 1 of 2 longs I've had for over a year. Largest position still.
-
bd4uandu: Glad you clarified that in other circles it has other meanings.
-
- View all 2 replies
-
Joseph P. Porter: From Bloomberg - it sounds as if the "correction" could become a Q2-long phenomenon, depending on earnings. They will have to pry $PFE out
-
Joseph P. Porter: of my cold, dead hands. Q2 tends to be a bit iffy, anyway. Much pessimism out there right now because of soft job #'s and Europe.
-
- View all 4 replies
-
-
-
- View all 28 replies
-
Jim Warlick: I've seen a large amount of research on ORCL and largely expect them to achieve 10-15% earnings this year. Watch developing cloud tech. BUY
-
-
- View all 4 replies
-
djamison: I know !!! Just when I was thinking things were are looking good !!
-
Joseph P. Porter: They're good - it's just best to not pay attention to their stock price. $PFE is the best performing stock I have had long term, so I cope.
-
Michael Bryant
"Zoetis's 17 percent sales growth in 2011 outpaced all but Lilly's animal unit..." Wonder how big a stake Pfizer ($PFE) still has. - View all 1 replies
-
